Bionano Genomics Inc BNGO Shares continued to trade higher on Wednesday after the company on Tuesday highlighted a study showing optical genome mapping is better at detecting structural variations in liver cancer.
In the study, optical genome mapping (OGM) helped reveal replication stress-induced events that may cause or contribute to genomic instability in cancer cells, potentially leading to oncogene activation and tumor suppressor disruption.
The study compared OGM to whole genome sequencing (WGS) and found that WGS detected only 63% of the variations detected by OGM.
“Cancer is often thought of as a disease with structural variation, and this study shows how OGM has the potential to elucidate the complex mechanisms of oncogenesis. It shows that OGM can be more sensitive to detecting large structural variations than WGS and it provides a nice example of how complementary the two methods are,” he said Eric HolmlinPresident and CEO of Bionano Genomics.
Bionano Genomics is a provider of genomic analysis solutions that enable researchers and clinicians to find answers to tough questions in biology and medicine.
BNGO Price Action: Bionano Genomics has a 52-week high of $4.35 and a 52-week low of $1.16.
The stock rose 13.3% on Tuesday and another 11.8% on Wednesday morning Gasoline Pro.
Photo: book chapter from Pixabay.
